Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) announced positive topline Phase 2b JASMINE results for nipocalimab in systemic lupus erythematosus (SLE) on January 6, 2026. The study met its primary endpoint (percentage achieving SRI-4 at Week 24 versus placebo) and key secondary/exploratory endpoints, including signals for steroid sparing. JASMINE enrolled 228 adults in a 52-week, randomized, double-blind, placebo-controlled, dose-ranging trial. Nipocalimab's safety and tolerability were consistent with prior Phase 2 studies with no new safety signals identified. Based on these topline results, the company plans to initiate a Phase 3 program for SLE; full study data will be presented at a future medical congress.

Positive

• JASMINE met primary SRI-4 endpoint at Week 24
• Study enrolled 228 adult participants
• Signals observed for steroid sparing
• No new safety signals identified versus prior Phase 2

Negative

• Results are topline only; full data pending presentation
• Phase 2 size limits certainty ahead of Phase 3 and approval

News Market Reaction – JNJ

+0.23%

1 alert

+0.23% News Effect

On the day this news was published, JNJ gained 0.23%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Study duration: 52 weeks Participants: 228 adults Primary endpoint timepoint: Week 24 +2 more

5 metrics

Study duration 52 weeks JASMINE Phase 2b SLE study

Participants 228 adults Randomized in JASMINE SLE trial

Primary endpoint timepoint Week 24 SRI-4 composite response vs placebo

Global SLE prevalence 3 to 5 million people Estimated worldwide systemic lupus erythematosus cases

U.S. SLE prevalence 450,000 people Estimated systemic lupus erythematosus cases in the U.S.

Market Reality Check

Price: $239.63 Vol: Today’s volume 9,136,600 ...

normal vol

$239.63 Last Close

Volume Today’s volume 9,136,600 vs 20-day average 7,893,403 (relative volume 1.16x). normal

Technical Price $204.31 is above 200-day MA of $174.34 and about 5.05% below 52-week high $215.19.

Peers on Argus

JNJ was down 1.47% while large-cap pharma peers were mixed: ABBV -3%, LLY -2.59%...

1 Up

JNJ was down 1.47% while large-cap pharma peers were mixed: ABBV -3%, LLY -2.59%, AZN +0.06%, NVS +0.57%, NVO +2.21% (also +4.08% in momentum scan). This points to stock-specific factors around JNJ’s news.

Historical Context

5 past events · Latest: Jan 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 02	Dividend declaration	Neutral	+0.2%	Announced Q1 2026 quarterly cash dividend of $1.30 per share.
Dec 29	Strategic acquisition	Positive	-0.0%	Closed $3.05B Halda Therapeutics deal adding oncology pipeline assets.
Dec 18	FDA approval	Positive	-1.0%	FDA approved expanded indication for TRUFILL n‑BCA in cSDH treatment.
Dec 17	FDA approval	Positive	-1.0%	FDA approved RYBREVANT FASPRO SC formulation for EGFR-mutated NSCLC.
Dec 15	Earnings conference	Neutral	-2.3%	Scheduled investor call to review fourth-quarter results and outlook.

Pattern Detected

Recent positive regulatory and acquisition headlines often coincided with flat-to-negative next-day price moves, suggesting a tendency toward muted or contrarian reactions even on good news.

Recent Company History

Over the last month, Johnson & Johnson announced a $1.30 Q1 2026 dividend, completed a $3.05 billion Halda Therapeutics acquisition, and secured two FDA approvals (TRUFILL n‑BCA and RYBREVANT FASPRO) alongside an investor call notice. Despite clearly constructive events, 24-hour reactions ranged from about flat to declines near -2%. Against this backdrop, today’s positive Phase 2 SLE results for nipocalimab extend a pattern where strong clinical or regulatory milestones have not always produced immediate upside.

Market Pulse Summary

This announcement highlights positive Phase 2b JASMINE results for nipocalimab in systemic lupus ery...

Analysis

This announcement highlights positive Phase 2b JASMINE results for nipocalimab in systemic lupus erythematosus, meeting its SRI-4 primary endpoint at Week 24 in 228 adults over a 52-week study. The safety profile matched prior studies, and Johnson & Johnson plans a Phase 3 program. In context of earlier nipocalimab and other immunology trial successes, investors may watch for full data presentations and Phase 3 design to gauge long-term strategic impact.

Key Terms

systemic lupus erythematosus, FcRn blocker, SLE Responder Index 4 (SRI-4), SELENA-SLE Disease Activity Index (SELENA-SLEDAI), +4 more

8 terms

systemic lupus erythematosus medical

"study of adults living with systemic lupus erythematosus (SLE)"

Systemic lupus erythematosus is a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissue, causing inflammation that can affect skin, joints, kidneys, heart, lungs and other organs. It matters to investors because disease severity, prevalence, and gaps in effective treatments drive demand for new drugs and diagnostics—think of it as a large, persistent market need where a successful therapy can change patient outcomes and create significant commercial value.

FcRn blocker medical

"first positive results of an investigational FcRn blocker treatment"

A fcrn blocker is a type of drug that interferes with the neonatal Fc receptor, a body ‘recycling’ system that preserves antibodies in the blood; by blocking it, the medicine lowers overall antibody levels, including harmful ones. Investors care because these drugs can treat a range of autoimmune and antibody-driven disorders; success or failure in clinical trials, regulatory approvals, or pricing can strongly affect a developer’s commercial prospects and valuation, much like a new technology that cuts demand for a common resource.

SLE Responder Index 4 (SRI-4) medical

"percentage of patients achieving Systemic Lupus Erythematosus Responder Index [SRI-4]"

SLE Responder Index 4 (SRI‑4) is a composite clinical measure used in lupus trials that signals meaningful patient improvement by combining three checks: a drop in disease activity of at least four points on a symptom score, no major new organ problems, and no overall worsening by the treating physician. For investors it matters because meeting the SRI‑4 in a clinical trial is often used to demonstrate a drug’s effectiveness, influencing regulatory approval chances and commercial prospects—like clearing key checkpoints on a product’s path to market.

SELENA-SLE Disease Activity Index (SELENA-SLEDAI) medical

"comprises criteria from three different internationally validated indices, SELENA-SLE Disease Activity Index"

A standardized clinical score that measures how active systemic lupus erythematosus (SLE) is by adding up specific symptoms and test results to produce a single number. Think of it as a medical report card: higher scores mean more disease activity, lower scores mean improvement. Investors watch SELENA-SLEDAI results from drug trials because changes in the score indicate whether a treatment is working, which affects regulatory approval, clinical value and market potential.

Physician Global Assessment (PGA) medical

"indices, SELENA-SLE Disease Activity Index (SELENA-SLEDAI), Physician Global Assessment (PGA)"

A physician global assessment (PGA) is a doctor’s overall rating of a patient’s illness severity or improvement, usually recorded on a simple numerical or verbal scale after examining symptoms and signs. Think of it as a single summary score a coach gives a player after watching a game: it captures overall performance at a glance. Investors care because PGA scores are often used in clinical trials to show whether a treatment visibly helps patients, which can affect regulatory approval, market acceptance and commercial value.

British Isles Lupus Assessment Group (BILAG) 2004 medical

"and the British Isles Lupus Assessment Group (BILAG) 2004."

A standardized clinical scoring system used to measure how active lupus (systemic lupus erythematosus) is in different organs and body systems; the 2004 version is an updated format of that tool. Investors care because it is commonly used as an endpoint in drug trials and regulatory evaluations—think of it as a multi-section report card that regulators and doctors use to judge whether a treatment is truly improving patients, which directly affects a therapy’s approval and market potential.

double-blind technical

"52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled technical

"randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

AI-generated analysis. Not financial advice.

The JASMINE study met the primary endpoint and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparing

SLE is one of the most prevalent and debilitating autoantibody diseases, causing one's own immune system to mistakenly attack various tissues, which can lead to potentially life-threatening systemic organ damage

Based on these positive topline results, the company plans to initiate a Phase 3 program for nipocalimab in SLE

SPRING HOUSE, Pa., Jan. 6, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a Phase 3 program. The JASMINE study met the primary endpoint (percentage of patients achieving Systemic Lupus Erythematosus Responder Index [SRI-4]^a composite response at Week 24 with statistical significance compared with placebo), and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparing. Nipocalimab had a safety and tolerability profile consistent with previous Phase 2 studies, with no new safety signals identified.

These data represent the first positive results of an investigational FcRn blocker treatment in this chronic, debilitating autoantibody-driven disease that impacts an estimated 3 to 5 million people worldwide, and 450,000 in the U.S.^1,2 Chronic symptoms of SLE include severe fatigue, joint pain and swelling, and rashes, including a hallmark butterfly-shaped facial rash.³

JASMINE is a 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of nipocalimab in 228 adult participants with active SLE and the first positive study of an FcRn blocker for the treatment of active SLE.⁴

"Systemic lupus erythematosus or SLE is a serious autoantibody-driven disease that can impact multiple organ systems, significantly reducing health-related quality of life for millions of people," said Leonard L. Dragone, M.D., Ph.D., Disease Area Leader, Autoantibody and Rheumatology, Johnson & Johnson Innovative Medicine. "Many people living with SLE also face complications associated with long-term steroid use, underscoring the limitations of current treatment approaches and the critical need for immunoselective therapies that are safe, tolerable, and capable of reducing disease activity, while preserving immune function."

Full results from the JASMINE study will be presented at a future medical congress.

Editor's note:

a. The SLE Responder Index 4 (SRI-4) is a composite measure used to assess treatment response in patients with SLE during clinical studies. It comprises criteria from three different internationally validated indices, SELENA-SLE Disease Activity Index (SELENA-SLEDAI), Physician Global Assessment (PGA) and the British Isles Lupus Assessment Group (BILAG) 2004.

ABOUT JASMINE

JASMINE (NCT04882878) is a 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of nipocalimab in 228 adult participants with active SLE and the first positive study of an FcRn blocker for the treatment of active SLE.⁴

ABOUT SYSTEMIC LUPUS ERYTHEMATOSUS

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that occurs when the body's immune system mistakenly attacks its own healthy tissues. This can lead to inflammation and damage in many parts of the body, including the skin, joints, heart, lungs, kidneys, and brain.⁵ SLE affects nine times more women than men, often striking initially between the ages of 15-44.⁶ In addition to systemic organ damage, other complications of SLE can include end-stage renal failure, scarring cutaneous lesions, neurological damage, and various forms of cardiovascular disease.⁵ People living with SLE often face reduced health-related quality of life, due to severe fatigue, mood disturbances, joint pain and swelling, and rashes, including the hallmark butterfly-shaped facial rash, as well as complications of long-term glucocorticoid use.³ Severe fatigue is the most widely reported and debilitating symptom of SLE, affecting up to 80% of people with SLE.⁷ SLE is the most common form of lupus, affecting 3 to 5 million people worldwide, approximately 70% of lupus cases.^1,6 It is estimated that 450,000 people in the United States are affected by SLE.²

ABOUT NIPOCALIMAB
Nipocalimab is an investigational monoclonal antibody, designed to bind with high affinity to block FcRn and reduce levels of circulating immunoglobulin G (IgG) antibodies potentially without additional detectable effects on other adaptive and innate immune functions. This includes autoantibodies and alloantibodies that underlie multiple conditions across three key segments in the autoantibody space including Rare Autoantibody diseases, Maternal Fetal diseases mediated by maternal alloantibodies and autoantibody-driven Rheumatic diseases.^{8,9,10,11,12,13,14,15,16} Blockade of IgG binding to FcRn in the placenta is also believed to limit transplacental transfer of maternal alloantibodies to the fetus.^17,18

The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted several key designations to nipocalimab including:   

• EU EMA Orphan medicinal product designation for hemolytic disease of the fetus and newborn (HDFN) in October 2019 and fetal and neonatal alloimmune thrombocytopenia (FNAIT) in April 2025
• U.S. FDA Fast Track designation in HDFN and warm autoimmune hemolytic anemia (wAIHA) in July 2019, gMG in December 2021, FNAIT in March 2024 and Sjögren's disease (SjD) in March 2025
• U.S. FDA Orphan drug status for wAIHA in December 2019, HDFN in June 2020, gMG in February 2021, chronic inflammatory demyelinating polyneuropathy (CIDP) in October 2021 and FNAIT in December 2023
• U.S. FDA Breakthrough Therapy designation for HDFN in February 2024 and for Sjögren's disease in November 2024
• U.S. FDA granted Priority Review in generalized myasthenia gravis in Q4 2024

ABOUT JOHNSON & JOHNSON
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.  

Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com.

Follow us at @JNJInnovMed. 

Janssen Research & Development, LLC, Janssen Biotech, Inc. and Janssen Global Services, LLC are Johnson & Johnson companies. 

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of nipocalimab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

¹ Tian, J., Zhang, D., Yao, X., Huang, Y., & Lu, Q. (2023). Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study. Annals of the Rheumatic Diseases, 82(3), 351–356. https://doi.org/10.1136/ard-2022-223035
² Wang, Y., Hester, L. L., Lofland, J., Rose, S., Karyekar, C.S., Kern, D.M., Blacketer, M., Davis, K., & Sheilds-Tuttle, K. (2022). Update on the prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016. BMC Research Notes, 15, 5. https://doi.org/10.1186/s13104-021-05877-1
³ Centers for Disease Control and Prevention. (2024). Symptoms of lupus. https://www.cdc.gov/lupus/signs-symptoms/. Last accessed: January 2026.
⁴ ClinicalTrials.gov Identifier: NCT04882878. Available at: https://clinicaltrials.gov/study/NCT04882878. Last accessed: January 2026.
⁵ National Institute of Arthritis and Musculoskeletal and Skin Disease. (2022) Systemic Lupus Erythematosus (Lupus). https://www.niams.nih.gov/health-topics/lupus. Last accessed: January 2026.
⁶ Ahn, G.E., & Ramsey-Goldman, R. (2012). Fatigue systemic lupus erythematosus. International Journal of Clinical Rheumatology, 7(2), 217–227. https://doi.org/10.2217/IJR.12.4
⁷ Lupus Foundation of America. Lupus facts and statistics. https://www.lupus.org/resources/lupus-facts-and-statistics. Last accessed: January 2026.
⁸ ClinicalTrials.gov. NCT03842189. Available at: https://clinicaltrials.gov/ct2/show/NCT03842189. Last accessed: January 2026.
⁹ ClinicalTrials.gov Identifier: NCT05327114. Available at: https://www.clinicaltrials.gov/study/NCT05327114. Last accessed: January 2026.
¹⁰ ClinicalTrials.gov Identifier: NCT04119050. Available at: https://clinicaltrials.gov/study/NCT04119050. Last accessed: January 2026.
¹¹ ClinicalTrials.gov Identifier: NCT05379634. Available at: https://clinicaltrials.gov/study/NCT05379634. Last accessed: January 2026.
¹² ClinicalTrials.gov Identifier: NCT05912517. Available at: https://www.clinicaltrials.gov/study/NCT05912517. Last accessed: January 2026.
¹³ ClinicalTrials.gov Identifier: NCT04968912. Available at: https://www.clinicaltrials.gov/study/NCT04968912. Last accessed: January 2026.
¹⁴ ClinicalTrials.gov Identifier: NCT04882878. Available at: https://clinicaltrials.gov/study/NCT04882878. Last accessed: January 2026.
¹⁵ ClinicalTrials.gov Identifier: NCT06449651. Available at: https://clinicaltrials.gov/study/NCT06449651. Last accessed: January 2026.
¹⁶ ClinicalTrials.gov Identifier: NCT06533098. Available at: https://clinicaltrials.gov/ct2/show/NCT06533098. Last accessed: January 2026.
¹⁷ Lobato G, Soncini CS. Relationship between obstetric history and Rh(D) alloimmunization severity. Arch Gynecol Obstet. 2008 Mar;277(3):245-8. DOI: 10.1007/s00404-007-0446-x. Last accessed: January 2026.
¹⁸ Roy S, Nanovskaya T, Patrikeeva S, et al. M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model. Am J Obstet Gynecol. 2019;220(5):498 e491-498 e499.

Media contact: Bridget Kimmel bkimmel@its.jnj.com

Investor contact: Lauren Johnson investor-relations@its.jnj.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-unveils-new-data-showing-nipocalimab-is-the-first-and-only-investigational-fcrn-blocker-with-potential-to-reduce-systemic-lupus-erythematosus-sle-activity-in-a-phase-2-study-302652952.html

SOURCE Johnson & Johnson

FAQ

What did Johnson & Johnson announce about nipocalimab for SLE on January 6, 2026?

Johnson & Johnson announced positive topline Phase 2b JASMINE results showing the study met the SRI-4 primary endpoint and plans to start a Phase 3 program.

How many patients were enrolled in the JASMINE Phase 2b study (JNJ) and what was the design?

JASMINE enrolled 228 adults in a 52-week, randomized, double-blind, placebo-controlled, dose-ranging study.

Did nipocalimab show any safety concerns in the Phase 2b JASMINE study (JNJ)?

The company reported nipocalimab had a safety and tolerability profile consistent with prior Phase 2 studies with no new safety signals.

What clinical endpoint did nipocalimab meet in JASMINE (JNJ) and when was it assessed?

Nipocalimab met the SLE Responder Index 4 (SRI-4) primary endpoint assessed at Week 24 versus placebo.

Will Johnson & Johnson start a Phase 3 trial for nipocalimab in SLE (JNJ)?

Yes. Based on the topline Phase 2b results, the company plans to initiate a Phase 3 program for SLE.

Are full JASMINE study results for nipocalimab (JNJ) available now?

No. The announcement referenced topline results; full results will be presented at a future medical congress.